Krystal Biotech Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	470.03	389.13	290.52	50.7	-	-
Revenue Growth	25.96%	33.95%	473.02%	-	-	-
Cost of Revenue	26.91	23.05	20.06	3.09	-	-
Gross Profit	443.12	366.08	270.45	47.61	-	-
Selling, General & Admin	156.06	146.74	113.63	98.29	78.84	41.99
Research & Development	59.53	58.05	53.58	46.43	42.46	27.88
Operating Expenses	215.59	204.79	167.21	144.72	121.3	69.88
Operating Income	227.52	161.3	103.25	-97.12	-121.3	-69.88
Interest Expense	-	-	-	-	-	-1.49
Interest & Investment Income	31.27	28.18	29.61	22.51	5.22	0.2
EBT Excluding Unusual Items	258.8	189.47	132.86	-74.6	-116.08	-71.17
Gain (Loss) on Sale of Assets	-	-	-	100	-	-
Legal Settlements	-	-	-37.5	-12.5	-25	-
Pretax Income	258.8	189.47	95.36	12.9	-139.98	-69.57
Income Tax Expense	33.63	-15.36	6.2	1.97	-	-
Net Income	225.17	204.83	89.16	10.93	-139.98	-69.57
Net Income to Common	225.17	204.83	89.16	10.93	-139.98	-69.57
Net Income Growth	13.20%	129.74%	715.58%	-	-	-
Shares Outstanding (Basic)	29	29	29	27	25	22
Shares Outstanding (Diluted)	31	30	30	28	25	22
Shares Change	2.44%	0.71%	7.16%	8.87%	14.85%	18.15%
EPS (Basic)	7.66	7.08	3.12	0.40	-5.49	-3.13
EPS (Diluted)	7.36	6.84	3.00	0.39	-5.49	-3.13
EPS Growth	10.50%	128.00%	669.23%	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Free Cash Flow	310.08	188.91	119.18	-100.6	-153.55	-116.27
Free Cash Flow Per Share	10.14	6.31	4.01	-3.63	-6.02	-5.24
Gross Margin	94.27%	94.08%	93.09%	93.90%	-	-
Operating Margin	48.41%	41.45%	35.54%	-191.56%	-	-
Profit Margin	47.91%	52.64%	30.69%	21.56%	-	-
Free Cash Flow Margin	65.97%	48.55%	41.02%	-198.43%	-	-
EBITDA	229.03	162.92	105.72	-93.21	-118.65	-67.11
EBITDA Margin	48.73%	41.87%	36.39%	-183.85%	-	-
D&A For EBITDA	1.51	1.62	2.47	3.91	2.64	2.77
EBIT	227.52	161.3	103.25	-97.12	-121.3	-69.88
EBIT Margin	48.41%	41.45%	35.54%	-191.56%	-	-
Effective Tax Rate	12.99%	-	6.50%	15.24%	-	-

SEC Filings: 10-K · 10-Q